Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[GnRH antagonists: present and future].

Philippe Bouchard1

  • 1Service d'endocrinologie, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. philippe.bouchard@sat.aphp.fr

Annales D'Urologie
|November 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poor sleep quality is associated with poorer oral health related quality of life in patients with chronic diseases.

Sleep & breathing = Schlaf & Atmung·2026
Same author

A proof-of-concept for a novel mandibular dental implant model in mice.

Clinical oral investigations·2026
Same author

Decoding Causality in Periodontal Medicine: Background Factors and Other Sources of Uncertainty.

Journal of periodontal research·2026
Same author

First in class monoclonal antibody potentiating human follicle stimulating hormone activity improves spermatogenesis in azoospermic rodent models.

Frontiers in endocrinology·2025
Same author

Prehabilitation in Implant Dentistry: An Essential Strategy for Primordial Prevention of Peri-Implant Diseases.

Journal of periodontal research·2025
Same author

Monoclonal antibody potentiating gonadotropin activity in vitro and in vivo in male and female rats and in ewes.

Reproduction (Cambridge, England)·2025
Same journal

Prostate cancer at the 2007 ASCO meeting: an urologist's perspective.

Annales d'urologie·2008
Same journal

[Surgical treatment of ureteropyelic junction stenosis using robotic-assisted laparoscopy].

Annales d'urologie·2008
Same journal

[Robotic-assisted laparoscopy: general principles].

Annales d'urologie·2008
Same journal

[De novo tumours of renal transplants].

Annales d'urologie·2008
Same journal

[Immunosuppression in kidney transplantation].

Annales d'urologie·2008
Same journal

[Surgical complications in kidney transplantation].

Annales d'urologie·2008
See all related articles

Gonadotropin-releasing hormone (GnRH) antagonists competitively inhibit pituitary receptors, suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Ongoing research explores new applications beyond assisted reproduction, despite development challenges.

Area of Science:

  • Reproductive Endocrinology
  • Pharmacology

Context:

  • GnRH antagonists are a class of drugs that inhibit the secretion of LH and FSH.
  • Currently, only a few GnRH antagonists are available, with specific applications in assisted reproduction and prostate cancer treatment.

Purpose:

  • To review the current status and future potential of GnRH antagonists.
  • To discuss their mechanisms of action, existing indications, and emerging therapeutic areas.

Summary:

  • GnRH antagonists bind to pituitary GnRH receptors, competitively inhibiting GnRH action and suppressing LH and FSH secretion for approximately 24 hours.
  • Available antagonists include Cetrorelix (in vitro fertilization, benign prostatic hypertrophy research), Ganirelix (assisted procreation), and Abarelix (prostate cancer).
  • Newer orally active antagonists are in development, but progress is hindered by industrial conflicts and tolerability issues, particularly histamine release side effects.

Related Experiment Videos

Impact:

  • Current French indications are limited to Assisted Reproductive Technology and prostate cancer, with ongoing studies comparing them to agonists.
  • Potential future indications include endometriosis, uterine fibroids, precocious puberty, and male contraception, though cost remains a barrier for some applications.
  • Intermittent administration may offer rapid urinary flow improvement in benign prostatic hypertrophy.